Lets generic drugs and similar medicines reach patients faster, potentially lowering costs.
This bill would make it easier for generic drug and biosimilar manufacturers to sell their products without facing patent lawsuits, even if they don't cover all uses of the original drug. This could mean more affordable medicines become available sooner for patients. The new rules would also apply to ongoing court cases.
Today, generic and biosimilar companies risk patent infringement lawsuits even if their product labels only cover unpatented uses. After this bill, they would be protected from such lawsuits, allowing them to bring their products to market more quickly and potentially lowering drug costs for consumers.
HR 6485 · 119th Congress · December 5, 2025 · AI Summary by gemini-2.5-flash · 8/10
Sign in to see your representatives' phone numbers
27 filings mentioned this bill
Amounts reflect total quarterly lobbying spend reported to the Senate, not bill-specific spending. Source: Senate LDA filings.